Boltz
Biomolecular AI company founded by MIT researchers and now based in London, building models to design molecules and proteins.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
๐๏ธ Deep Dive
Boltz, Mistral AI, Elysian Aircraft โ capital for drug discovery, sovereign AI and electric aviation โ Daily News November 19, 2026
Listen to the episodeAbout Boltz
Boltz is a public benefit company founded in 2025 by Gabriele Corso (CEO), Jeremy Wohlwend and Saro Passaro, MIT researchers known for open-source biomolecular structure prediction models. Started in the United States, it is now based in London's King's Cross, where about 40 researchers and engineers work. It develops the BoltzMol-1 and BoltzProt-1 models, available via API, and the Boltz Lab platform for scientists and AI agents; it reports signed partnerships with six of the world's 20 largest pharma companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb, and 50-fold growth in molecular token volume among paying customers since June. After a $28 million seed round in January 2026, on 18 November 2026 it announced a $110 million Series A led by Bessemer Venture Partners, with Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures returning and Greycroft, F-Prime Capital, Hummingbird and Benchling joining. The money will go into compute, data and hiring. Nvidia also announced an investment in 2026, with no amount disclosed.
The Story
Founded in 2025 by three MIT researchers, Gabriele Corso, Jeremy Wohlwend and Saro Passaro, and later relocated to London.
How Boltz works
Business Model
Partnerships with pharma companies and paid access to models and platform.
Revenue Model
Partnerships and access to the platform and models.
Products & Services
Key Products
- BoltzMol-1
- BoltzProt-1
- Boltz Lab
Core Use Cases
- Small-molecule design
- Protein design
- Biomolecular structure prediction
Market & Clients
Key Customers
Large pharma companies, biotechs and research labs.
Geographic Presence
How Boltz competes
Competitive Advantages
- Open-source models widely adopted by the scientific community
- Partnerships with major pharma groups
How Boltz grows
Growth Strategy
Invest in compute and data, meet partner demand and expand the team.
Distribution Model
API, the Boltz Lab platform and direct partnerships.
Key Risks
- Competition in AI drug discovery
- Experimental validation of model outputs
- Compute costs
Strategic Insights
- Its open-source origins built a user community before commercialisation.
- The move to London brings one of the emerging AI-for-biology companies to Europe.
Funding & Investors
Total Funding
Funding Rounds
- 2026 - Series A: $110M
Lead: Bessemer Venture Partners - 2026 - Seed: $28M
Key Investors
Founding Team
Founders
Key Metrics
Lessons from Boltz
- Releasing open-source models can speed up adoption and open the door to commercial partnerships with large customers.
Similar Startups
Isomorphic Labs
Isomorphic Labs applies advanced AI models โ including those underlying AlphaFold โ to drug discovery and design, aiming to transform molecular biology into a computational process and radically accelerate therapeutic pipelines.
Read AnalysisBabylon Health
Company born in London in 2013 with digital doctor consultations and AI tools for patients. A unicorn in 2019, listed on the NYSE in 2021, assets sold to eMed in 2023.
Read AnalysisFrontier Health
London healthtech developing Juno, an AI agent supporting hospital administrative staff.
Read AnalysisSources
- Announcing our Series A — Boltz
- London-based Boltz raises $110M Series A — Tech.eu
- Boltz bags $28M funding and Pfizer partnership — TechRepublic
- Boltz โ company profile — Dealroom